French Innovative Leukemia Organisation

This study is testing a combination of two drugs, tagraxofusp and venetoclax, for adults newly diagnosed with a rare and aggressive blood cancer called BPDCN. The main goal is to see if this combination leads to a complete remission after three months of treatment. Depending on t…

This study is testing whether a combination of two oral drugs, zanubrutinib and BGB-11417, can effectively control a rare blood cancer called Waldenström's macroglobulinemia in patients whose disease has returned after prior treatment. The goal is to see if this limited-duration …

This study is testing whether taking two oral medications, ivosidenib and azacitidine, can help keep a specific type of acute myeloid leukemia (AML) from coming back in older adults. It is for patients aged 55+ who have achieved remission after intensive chemotherapy and have a s…